Multicenter review of a tadalafil suspension formulation for infants and children with pulmonary hypertension: A North American experience

INTRODUCTION: Phosphodiesterase type 5 (PDE5) inhibitors, with sildenafil the earliest among them, are widely used in the management of pediatric pulmonary arterial hypertension (PAH). Tadalafil is a PDE5 inhibitor with a long half life (16 h), stable pharmacokinetics and pharmacodynamics, and minim...

Descripción completa

Detalles Bibliográficos
Autores principales: Youssef, David Edward, Handler, Stephanie S., Richards, Susan Marjorie, Sheppard, Catherine Anne, Smith, Jenna, Tillman, Kathryn, Pietrosanu, Matthew, Kirkpatrick, Edward, Bates, Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909267/
https://www.ncbi.nlm.nih.gov/pubmed/36776903
http://dx.doi.org/10.3389/fped.2023.1055131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909267/
https://www.ncbi.nlm.nih.gov/pubmed/36776903
http://dx.doi.org/10.3389/fped.2023.1055131

Ejemplares similares